City Bio

City Therapeutics is a biotechnology company dedicated to advancing the next generation of RNA interference (RNAi) therapies. Founded by industry leaders from Alnylam and ARCH Venture Partners, the company leverages a proprietary platform to engineer optimized small interfering RNAs (siRNAs) with enhanced potency and durability. City Therapeutics aims to expand the therapeutic reach of RNAi beyond traditional liver-targeted delivery, focusing on a broad range of indications including rare and prevalent diseases. The company's approach involves "bespoke" engineering of RNAi triggers to maximize clinical impact and safety. By integrating cutting-edge RNA chemistry with novel delivery technologies, City Therapeutics seeks to create a sustainable engine for transformative genetic medicines.